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Summary
The US-American Women’s Health Initiative Observa-
tional Study (WHI-OS) is a prospective cohort study in
postmenopausal women aged 50–79 at study entry
(n = 93,676). Annual follow-up was performed by mailed
self-administered questionnaires including questions on
menopause hormone therapy (MHT). The aim of the
present analysis was to compare the impact of various
MHT formulations and route of delivery on incident car-
diovascular diseases (CVD) [1]. Therefore, only current
MHT users were included (n = 41,721; 45 % of total
cohort). MHT subgroups were defined as follows: (1) oral
low-dose conjugated equine estrogens (CEE) (\0.625
mg/day), (2) oral standard-dose CEE (0.625 mg/day), (3)
oral high-dose CEE ([0.625 mg/day), (4) oral estrogens
[CEE or estradiol (E2)], (5) oral estrogen plus progestogen
therapy (EPT) (oral CEE or E2 plus progestin or proges-
terone), and (6) transdermal E2 therapy (ET) of any dosage
plus oral progestin or progesterone in women with an intact
uterus. Study endpoints were (1) major coronary heart
disease (CHD) (nonfatal myocardial infarction, coronary
death), (2) stroke, (3) CVD mortality, (4) total CVD (major
CHD, stroke, CVD mortality), and (5) all-cause mortality.
All analyses (Cox proportional hazards model) were
adjusted for established CVD risk factors as well as for
time since menopause (\10 vs. C10 years), and duration of
MHT use (\5 vs. C5 years), respectively.
The mean duration of follow-up was 10.4 years. The
majority of women used oral CEE (n = 29,944), mostly as
a standard-dose preparation (82 %) and without a com-
bined progestogen (55 %). In contrast, use of oral E2
(n = 3,024) or transdermal E2 (n = 2,187) was much less
common. However, the exact sample sizes of subgroups for
different oral/transdermal E2 dosages, and for E2 with or
without a progestogen, respectively, were not provided.
The main findings are summarized in Table 1. Time since
menopause and duration of MHT use did not have an
impact on cardiovascular risks. Absolute CVD risks and
all-cause mortality were lower in MHT user close to
menopause (no p-level provided). The authors concluded
that (1) estrogen dosage, route of delivery and type of
estrogen only had a minor impact on CVD risk, however,
(2) oral E2 might be associated with a lower risk of stroke,
and (3) transdermal MHT and oral low-dose CEE might be
associated with a lower risk of CHD compared to oral
standard-dose CEE.
Background
Cardiovascular diseases are the main cause of death in
women. Thus, any contributing risk factor should be avoided
if possible. MHT is considered the most effective treatment
for vasomotor symptom relief in postmenopausal women
[2]. However, several studies have shown an increased CVD
risk within the first year of MHT initiation [3–7]. The stan-
dard estrogen and progestogen used in those trials were oral
CEE and medroxyprogesterone acetate (MPA), respectively.
Furthermore, the majority of trials chose oral CEE at a
dosage of 0.625 mg/day considered as standard-dose CEE
today. Due to the initial CVD risk increase when starting oral
MHT, the question arose if type of estrogen, route of delivery
and estrogen dosage may have an impact on CVD risk. An
alternative estrogen type is estradiol (E2), transdermal
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patches and gels are an alternative route of delivery, and
nowadays various estrogen dosages are available ranging
from high-dose, standard-dose, low-dose to ultralow-dose
estrogen [8]. Possibly, physiological E2 has a better phar-
macodynamic and pharmacokinetic profile compared to
CEE, a complex of multiple biologically active estrogens [9].
The advantage of transdermal estrogen application is
avoiding the hepatic first-pass-effect causing a pro-coagu-
lant state [10, 11]. And finally, the effect of estrogens on
CVD risk might be dose-dependent, possibly making the
lowest dosage the safest one.
So far, there are two large-scale trials investigating the
impact of estrogen dosage and route of delivery on risk of
stroke [12, 13]. First, in a population-based nested case–
control study comparing 15,710 stroke survivors with
59,958 controls, transdermal estrogen therapy did not reveal
an increased risk of stroke for up to an estrogen dosage of
50 lg/day (adjusted RR 0.81, 95 % CI 0.62–1.05), while
oral low- and standard-dose estrogen therapy increased the
risk of stroke appreciably (adjusted RR 1.28, 95 % CI
1.15–1.42) even after thorough adjustment for known risk
factors for stroke [12]. Second, in comparison to never
MHT user, a prospective cohort study, the Nurses’ Health
Study, found a significantly increased risk of stroke in
postmenopausal women using oral standard- (adjusted RR
1.54, 95 % CI 1.31–1.81) or high-dose CEE (adjusted RR
1.62, 95 % CI 1.23–2.14) but not in those using oral low-
dose CEE (adjusted RR 0.93, 95 % CI 0.62–1.40) [13].
There are only few larger studies investigating the impact of
estrogen formulation on ischemic heart disease. First, in a
population-based nested case–control study comparing
1,013 myocardial infarction survivors with 5,000 controls
MHT was shown to reduce the risk of myocardial infarction
regardless of route of delivery (oral estrogens: adjusted OR
0.66; 95 % CI 0.50–0.88, and transdermal E2: adjusted OR
0.75; 95 % CI 0.47–1.21) [14]. Similarly, in the second
population-based nested case–control study comparing
4,537 myocardial infarction survivors with 27,220 controls
current and past MHT use was associated with a decreased
risk of myocardial infarction regardless of route of delivery
(oral MHT: adjusted OR 0.77, 95 % CI 0.66–0.90, and
transdermal MHT: adjusted OR 0.66, 95 % CI 0.49–0.88)
[15]. The Danish Sex Hormone Register Study (DaHo RS),
a prospective cohort study, found a neutral effect on risk of
myocardial infarction for any current MHT use (RR 1.03,
95 % CI 0.95–1.11). Subgroup analysis revealed a signifi-
cantly lower risk with transdermal route of delivery com-
pared to oral unopposed estrogen therapy (p = 0.04) [16].
There are two not yet published RCT in postmenopausal
women addressing the impact of 5 years of treatment with
different estrogen types and route of delivery on surrogate
markers of cardiovascular health with carotid media–
intima-thickness (CIMT) progression as primary endpoint.
The RCT Kronos Early Estrogen Prevention Study
(KEEPS) compares the impact of low-dose oral or trans-
dermal E2 with placebo in recently postmenopausal
women, respectively [17]. The RCT Early versus Late
Intervention Trial with Estradiol (ELITE) compares the
impact of oral low-dose E2 (± micronized progesterone)
with placebo in either early or late postmenopausal women,
respectively (ClinicalTrials.gov Identifier: NCT00114517).
So far, preliminary results have been presented at inter-
national conferences on menopause revealing either a
positive (ELITE; International Menopause Society, Cancun
2014), or neutral (KEEPS; North American Menopause
Society, Orlando 2012) effect of E2 on CIMT progression
in early postmenopausal women, respectively. In both tri-
als, risks of coronary and cerebrovascular disease were not
increased in MHT user.
Comment
This prospective cohort study, WHI-OS, is the largest study
to date investigating the impact of different estrogen types,
route of delivery and estrogen dosages on various single
Table 1 Comparison of various
MHT formulations on cardio-
and cerebrovascular risk
CEE conjugated equine
estrogens, E2 estradiol, MHT
menopause hormone therapy,
CVD cardiovascular disease,
CHD coronary heart disease,
low-dose \0.625 mg
CEE/day, standard-dose
0.625 mg CEE/day
Reference Comparator Results
Oral MHT
(= standard-dose
CEE ± progestogen)
Transdermal MHT (= E2 at
any dosage ± progestogen)
In favor of transdermal MHT: non-significant
risk reduction for all CVD endpoints (most
pronounced for major CHD: HR 0.63, 95 %
CI 0.37–1.06) but not for all-cause mortality
Oral low-dose MHT (= low-
dose CEE ± progestogen)
In favor of low-dose MHT: Non-significant risk
reduction for major CHD, total CVD and CVD
mortality but not for stroke and all-cause
mortality
Oral MHT containing E2
(= oral E2 at any
dosage ± progestogen)
In favor of MHT containing E2: non-significant
risk reduction of stroke (HR 0.64, 95 % CI
0.40–1.02) but no impact on other endpoints
Oral standard-dose
CEE alone
Oral combined MHT (= CEE/
E2 ± progestogen)
No significant difference for any endpoint
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and combined cardiovascular endpoints. However, despite
the large sample size and long duration of follow-up, the
present WHI-OS analysis may not give a definite statement
on whether or not transdermal and low-dose MHT display
a more beneficial cardiovascular profile than oral or stan-
dard-dose MHT, respectively. First, due to the observa-
tional nature of the WHI-OS, selection bias through
allocation of transdermal estrogen to women at risk for
CHD and stroke cannot be excluded and would mitigate
any result in favor of the transdermal route. Secondly,
sample sizes of women using transdermal MHT
(n = 2,187), and oral low-dose CEE (n = 2,149) were
quite small. Accordingly, subgroup analysis for different
E2 dosages in transdermal MHT or progestogen type in
combined MHT would not have been reliably possible.
Next, risk assessment for each endpoint was based on
baseline MHT use. Thus, the analysis did not account for
possible modifications of MHT formulation during follow-
up. Finally, the study only included current MHT user.
However, previous studies have shown an increased car-
diovascular risk within the first year after MHT initiation,
especially for oral estrogens. Thus, the increased incidence
of cardiovascular events within the first year of MHT use
may have been missed which may lead to an underesti-
mation of the prevalence of cardiovascular events. In
conclusion, the WHI-OS provides further hints for a safer
cardiovascular profile of transdermal MHT. Data from
RCTs like KEEPS will hopefully add more profound
information.
References
1. Shufelt CL, Merz CN, Prentice RL, Pettinger MB, Rossouw JE,
Aroda VR, Kaunitz AM, Lakshminarayan K, Martin LW, Phillips
LS, Manson JE (2014) Hormone therapy dose, formulation, route
of delivery, and risk of cardiovascular events in women: findings
from the Women’s Health Initiative Observational Study. Men-
opause 21:260–266. doi:10.1097/GME.0b013e31829a64f9
2. de Villiers TJ, Gass ML, Haines CJ, Hall JE, Lobo RA, Pierroz
DD, Rees M (2013) Global Consensus Statement on menopausal
hormone therapy. Maturitas 74:391–392. doi:10.1016/j.maturitas.
2013.02.001
3. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooper-
berg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV,
Johnson KC, Kotchen JM, Ockene J, Writing Group for the
Women’s Health Initiative I (2002) Risks and benefits of estrogen
plus progestin in healthy postmenopausal women: principal
results From the Women’s Health Initiative randomized con-
trolled trial. JAMA 288:321–333
4. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Ros-
souw JE, Prentice RL, Anderson G, Howard BV, Thomson CA,
LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M,
Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA,
Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller
LH, Lewis CE, Liu S, Martin LW, Ockene JK, O’Sullivan MJ,
Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB
(2013) Menopausal hormone therapy and health outcomes during
the intervention and extended poststopping phases of the
Women’s Health Initiative randomized trials. JAMA
310:1353–1368. doi:10.1001/jama.2013.278040
5. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser
NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland
OL, Wong ND, Crouse JR, Stein E, Cushman M, Women’s
Health Initiative I (2003) Estrogen plus progestin and the risk of
coronary heart disease. N Engl J Med 349:523–534. doi:10.1056/
NEJMoa030808
6. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE,
Stampfer MJ (2000) A prospective, observational study of post-
menopausal hormone therapy and primary prevention of cardio-
vascular disease. Ann Intern Med 133:933–941
7. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B,
Vittinghoff E (1998) Randomized trial of estrogen plus progestin
for secondary prevention of coronary heart disease in postmen-
opausal women. Heart and Estrogen/progestin Replacement
Study (HERS) Research Group. JAMA 280:605–613
8. Birkhauser MH, Panay N, Archer DF, Barlow D, Burger H,
Gambacciani M, Goldstein S, Pinkerton JA, Sturdee DW (2008)
Updated practical recommendations for hormone replacement
therapy in the peri- and postmenopause. Climacteric 11:108–123.
doi:10.1080/13697130801983921
9. Bennink HJ (2008) Reprint of Are all estrogens the same? Mat-
uritas 61:195–201
10. Zegura B, Guzic-Salobir B, Sebestjen M, Keber I (2006) The
effect of various menopausal hormone therapies on markers of
inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in
healthy postmenopausal women. Menopause 13:643–650. doi:10.
1097/01.gme.0000198485.70703.7a
11. Brosnan JF, Sheppard BL, Norris LA (2007) Haemostatic acti-
vation in post-menopausal women taking low-dose hormone
therapy: less effect with transdermal administration? Thromb
Haemost 97:558–565
12. Renoux C, Dell’aniello S, Garbe E, Suissa S (2010) Transdermal
and oral hormone replacement therapy and the risk of stroke: a
nested case–control study. BMJ 340:c2519. doi:10.1136/bmj.
c2519
13. Grodstein F, Manson JE, Stampfer MJ, Rexrode K (2008) Post-
menopausal hormone therapy and stroke: role of time since
menopause and age at initiation of hormone therapy. Arch Intern
Med 168:861–866. doi:10.1001/archinte.168.8.861
14. Varas-Lorenzo C, Garcia-Rodriguez LA, Perez-Gutthann S, Du-
que-Oliart A (2000) Hormone replacement therapy and incidence
of acute myocardial infarction. A population-based nested case–
control study. Circulation 101:2572–2578
15. de Vries CS, Bromley SE, Farmer RD (2006) Myocardial
infarction risk and hormone replacement: differences between
products. Maturitas 53:343–350. doi:10.1016/j.maturitas.2005.06.
004
16. Lokkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger
C, Lidegaard O (2008) Hormone therapy and risk of myocardial
infarction: a national register study. Eur Heart J 29:2660–2668.
doi:10.1093/eurheartj/ehn408
17. Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Mer-
riam GR, Miller VM, Naftolin F, Santoro N (2005) KEEPS: the
Kronos Early Estrogen Prevention Study. Climacteric 8:3–12.
doi:10.1080/13697130500042417
Arch Gynecol Obstet (2014) 290:617–619 619
123
